Three of those pathways specifically the LXR/RXR activation, neuroprotective role for THOP1 in Alzheimer’s disease, and glutamate receptor signaling pathways, shift from being up- to mostly downregulated as approaching advanced cancer stage III. This evidence concerns the gene THOP1 and Alzheimer disease.